INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION
MOTILIUM® 1 mg/mL suspension.

SCHEDULING STATUS
Schedule 2.

PROPRIETARY NAME
(and dosage form)

MOTILIUM^® 1 mg/mL suspension.

COMPOSITION
Each mL contains 1 mg domperidone, with 0,18 % m/v methylparaben and 0,02 % m/v propylparaben as preservatives.

PHARMACOLOGICAL CLASSIFICATION
A.5.7.2 Anti-emetics and anti-vertigo preparations.

PHARMACOLOGICAL ACTION
Domperidone is a dopamine-receptor blocking agent. Its action on the dopamine-receptors in the chemo-emetic trigger zone produces an anti-emetic effect.
Domperidone does not cross the blood-brain barrier to any appreciable degree and so exerts relatively little effect on cerebral dopaminergic receptors.
Domperidone has been shown to increase the duration of antral and duodenal contractions, to increase the gastric emptying.
Domperidone does not alter gastric secretions and has no effect on intracranial pressure or on the cardiovascular system.
Domperidone is rapidly absorbed, with peak plasma concentrations approximately 1 hour after oral administration.
The absolute bio-availability of oral domperidone is low (approximately 15%) due to first-pass hepatic and intestinal metabolism.
Domperidone is 91 - 93% bound to plasma proteins. The plasma half-life after a single oral dose is 7 - 9 hours in healthy subjects but is prolonged in patients with severe renal insufficiency.
Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N-dealkylation. In vitro metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation. Urinary and faecal excretion amount to 31% and 66% of the oral dose, respectively. The proportion of drug, excreted unchanged is small (approximately 1% of urinary and 10% of faecal excretion).

INDICATIONS
MOTILIUM is indicated for:

-	Delayed gastric emptying of functional origin with gastro-oesophageal reflux and/or dyspepsia.
-	Control of nausea and vomiting of central or local origin.
-	As an anti-emetic in patients receiving cytostatic and radiation therapy.
-	Facilitates radiological examination of the upper gastrointestinal tract.

CONTRA-INDICATIONS
MOTILIUM is contra-indicated in patients with known sensitivity to domperidone.
MOTILIUM should not be used whenever stimulation of gastric motility is to be avoided or could be harmful, e.g. in the presence of gastro-intestinal haemorrhage, obstruction or perforation.
MOTILIUM is also contra-indicated in patients with a prolactin releasing pituitary tumour (prolactinoma).
The safety of use during pregnancy and lactation has not been established.

DOSAGE AND DIRECTIONS FOR USE
Acute conditions (mainly nausea, vomiting, hiccup)
Adults: 20 mg (20 mL of suspension or 4 medicine measures) 3 - 4 times per day, 15 to 30 minutes before meals and, if necessary, before retiring.
Children: 5 mg (5 mL of suspension or 1 medicine measure) per 10 kg body mass, 3 - 4 times per day, 15 to 30 minutes before meals and, if necessary before retiring.
Chronic conditions (mainly dyspepsia)
Adults: 10 mg (10 mL of suspension or 2 medicine measures) taken 3 times per day, 15 to 30 minutes before meals and, if necessary, before retiring. The dosage may be doubled.
Children: 2,5 mg (2,5 mL suspension or ½ a medicine measure) per 10 kg body mass taken 3 times per day, 15 to 30 minutes before meals and, if necessary before bedtime.

Directions for use
The bottle comes with a child-proof cap, and should be opened as follows: {illustrated}

1.	push the plastic screw cap down,
2.	while pressing down, turn the cap counter clockwise.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS
Side-effects
Allergic reactions, such as rash or urticaria, have been reported.
Abdominal cramps have been reported.
Dystonic reactions (extrapyramidal phenomena) may occur.
Reversible raised serum prolactin levels have been observed which may lead to galactorrhoea and gynaecomastia.
Hypertensive crises in patients with phaeochromocytoma may occur with administration of domperidone.
Where the blood brain barrier is not fully developed (mainly in young babies) or is impaired, the possible occurrence of neurological side-effects cannot be totally excluded.
Special precautions
MOTILIUM should be used with caution in patients with renal impairment or in those at risk of fluid retention. In patients with severe renal insufficiency (serum creatinine more than 6 mg/100 mL, i.e. more than 0,6 mmol/L) the elimination half-life of domperidone was increased from 7,4 to 20,8 hours. The dosing frequency should be reduced to once or twice daily, depending on the severity of impairment, and the dose may need to be reduced. Patients on prolonged therapy should be reviewed regularly.
Since domperidone is highly metabolised in the liver, MOTILIUM should be used with caution in patients with hepatic impairment (and in the elderly).
Interactions
Concomitant administration of anti-cholinergic drugs may inhibit the anti-dyspeptic effects of MOTILIUM.
Anti-muscarinic agents and opioid analgesics may antagonise the effect of MOTILIUM.
MOTILIUM suppresses the peripheral effects (digestive disorders, nausea and vomiting) of dopaminergic agonists.
Since MOTILIUM has gastro-kinetic effects, it could influence the absorption of concomitant orally administered medicines, particularly those with sustained release or enteric coated formulations.
As MOTILIUM interferes with serum prolactin levels, it may interfere with other hypoprolactinaemic agents and with some diagnostic tests.
Antacids and anti-secretory agents lower the oral bioavailability of domperidone. They should be taken after meals and not before meals, i.e. they should not be taken simultaneously with MOTILIUM.
Reduced gastric acidity impairs the absorption of domperidone. Oral bioavailability is decreased by prior administration of cimetidine or sodium carbonate.
The main metabolic pathway of domperidone is through CYP3A4. In vitro data suggests that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone. Examples of CYP3A4 inhibitors include the following:
-        azole antifungals
-        macrolide antibiotics
-        HIV protease inhibitors
-        nefazodone.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
Symptoms of overdosage may include drowsiness, disorientation and extrapyramidal reactions, especially in children.
Anticholinergic, anti-parkinson medicines or antihistamines with anticholinergic properties may be helpful in controlling the extrapyramidal reactions. There is no specific antidote to domperidone but in the event of overdosage, gastric lavage as well as the administration of activated charcoal may be useful. Symptomatic and supportive measures are recommended.

IDENTIFICATION
White suspension with a sweet taste.

PRESENTATION
100 mL or 200 mL amber glass bottles.

STORAGE INSTRUCTIONS
Store below 25°C. Protect from light.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER
V/5.7.2/19

NAME AND BUSINESS ADDRESS OF THE APPLICANT
JANSSEN-CILAG
JANSSEN PHARMACEUTICA (PTY) LTD
(Reg. No. 80/11122/07)
15th Road
HALFWAY HOUSE
1685

DATE OF PUBLICATION OF THIS PACKAGE INSERT
29 April 1993

        Code No:023926
        2000F
        Britepak

® Trademark

Updated on this site: January 2001
Current: May 2005
Source: Pharmaceutical Industry
SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2005